Phase II Study of BI 764532 Added to Platinum Chemotherapy in Adults with Advanced Large‑Cell Neuroendocrine Lung Cancer

2 1 1

What is this study about?

The study focuses on adults with large-cell neuroendocrine carcinoma of the lung, a rare type of lung cancer that has spread locally or to other parts of the body and cannot be cured with surgery. The usual first‑line treatment for this disease is a chemotherapy regimen that contains a platinum drug, which works by damaging the DNA of cancer cells. In this trial, the standard chemotherapy is combined with a new medication called obrixtamig, which is designed to help the body’s own T‑cells recognize and attack the cancer.

The main goal of the trial is to see whether adding obrixtamig to the standard chemotherapy can improve overall survival, meaning the length of time patients live after starting treatment.

Participants will receive the regular platinum‑based chemotherapy according to usual schedules and will also receive an intravenous infusion of obrixtamig during the same treatment cycles. After the treatment period, patients will be monitored for several months to track their health status and any side effects, with regular visits to assess how well the cancer is controlled and to record survival outcomes.

1 enrollment and baseline assessments

after joining the study you will sign an informed consent form that explains the trial.

the study team will collect basic health information, perform physical examinations, and obtain laboratory tests and imaging to confirm eligibility.

2 start of treatment

treatment begins with the standard-of-care platinum-based chemotherapy that is normally used for this type of lung cancer.

at the same time you will receive bi 764532, a bispecific t‑cell engager, administered by intravenous infusion.

3 study drug infusion schedule

the infusion of bi 764532 is given according to the study protocol; the exact dose, frequency, and length of each infusion are determined by the investigators and will be followed throughout the treatment period.

4 regular monitoring visits

you will attend scheduled clinic visits where blood samples are taken and imaging studies are performed to check how the cancer is responding and to monitor safety.

any side effects are evaluated and managed according to standard medical practice.

5 continuation of therapy

treatment continues for multiple cycles as long as the cancer does not progress and side effects remain acceptable.

the number of cycles and total duration are defined by the study protocol.

6 end‑of‑treatment assessment

when treatment is stopped, a final set of examinations is performed to document the overall response of the disease.

the results are used to evaluate the primary outcome of the trial, which is overall survival.

7 post‑treatment follow‑up

after completing therapy you will be followed for a period of time during which survival and any late effects are recorded.

follow‑up visits may include routine health checks and occasional imaging, as specified by the study schedule.

Who Can Join the Study?

You must sign a written consent form and be able to understand and agree to join the study.
You must have a lung cancer called large‑cell neuroendocrine carcinoma (LCNEC) that has been confirmed by a tissue test (called histology) and a lab test that looks for specific proteins (immunohistochemistry). If your tumor contains more than one type of cancer, at least half of it must be LCNEC.
The cancer must be locally advanced or have spread to other parts of the body (metastatic) and there must be no chance for a cure with surgery or radiation.
You must have already received exactly one cycle (one round) of standard chemotherapy that includes the drugs platinum and etoposide, with or without a medicine that helps the immune system fight cancer (called an immune checkpoint inhibitor). You cannot have had any other whole‑body (systemic) cancer treatment before.
Your cancer must be measurable, meaning doctors can see and measure it on scans using the standard criteria called RECIST version 1.1.
You must be an adult (usually 18 years or older) and can be male or female.

Who Cannot Join the Study?

You cannot join if you have symptomatic brain metastases – meaning cancer that has spread to the brain and is causing symptoms.
You cannot join if you have leptomeningeal disease – cancer cells that are present in the thin membranes covering the brain and spinal cord.
You cannot join if you have already received any systemic treatment (medicines that travel throughout the whole body) for metastatic disease, unless it was only one cycle of the standard chemotherapy described in the study’s inclusion rules.
You cannot join if you have previously been treated with obrixtamig or any anti‑DLL3 drug, including special experimental medicines called T‑cell engagers or antibody‑drug conjugates.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz	Mainz	Germany
Technische Universitaet Dresden	Dresden	Germany

Other Sites

Site Name	City	Country
LungenClinic Grosshansdorf GmbH	Grosshansdorf	Germany
Poesjrubzenqy Oiivllxbn	Oldenburg In Holstein	Germany
Gcrtpd Uruarfknbs Fqxzautld	Frankfurt	Germany
Lobiysurqbkb Hicux Dwjxturja Gubvwtqasevilrvvewdydksgyctro Gemj	Hemer	Germany
Tdodcjuryjvz Hbsbvdjgce gtpsa	Heidelberg	Germany
Unzaolbfqqikoewyuqbzs Eeeon Apn	Essen	Germany
Rueniv Bknkh Gnmfrfrhqohm fbsx mozoezzzrbyc Fljrtsete mxc	Stuttgart	Germany
Apifiyqip Kuxgko Gupihyh Gqct	Gauting	Germany
Etwfrgvfmhlz Lqcwuoqifbwb Bbvems Kifksyccxotpwooouiy gdhhq	Berlin	Germany

Trial status

Country	Status	Recruitment Start
Germany	Not yet recruiting	01.09.2026

Trial locations

Investigated Drugs:

Igg-Like T Cell Engager Binding To Dll3 And Cd3

obrixtamig (code name BI 764532) is a special type of medicine called a bispecific T‑cell engager. It is designed to attach to a protein called DLL3 on the cancer cells and to CD3 on the body’s T‑cells (a kind of immune cell). By linking the T‑cells to the cancer cells, it helps the immune system find and destroy the tumor. The drug is given through an intravenous (IV) infusion.

platinum‑based chemotherapy is the standard treatment used for advanced large‑cell neuroendocrine carcinoma of the lung. It includes chemotherapy drugs that contain a platinum compound (such as cisplatin or carboplatin). These drugs work by damaging the DNA inside cancer cells, which stops the cells from growing and leads them to die. This therapy is given as part of the usual first‑line treatment for this type of lung cancer.

large-cell neuroendocrine carcinoma of the lung – It is a rare type of lung cancer that arises from neuroendocrine cells and is composed of large malignant cells. The tumor often forms a sizable mass within the lung and can involve nearby lymph nodes. As it grows, it may invade surrounding lung tissue and chest structures. Over time, cancer cells can spread through the bloodstream or lymphatic system to distant organs such as the liver, brain, or bones. The disease can progress from a locally advanced stage to widespread metastasis.

Trial ID:

2025-524345-28-00

Protocol code:

TUD-ALPIN2-089

NCT ID:

NCT07561645

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Phase II Study of BI 764532 Added to Platinum Chemotherapy in Adults with Advanced Large‑Cell Neuroendocrine Lung Cancer

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?